Ligand Pharmaceuticals Incorporated (LGND) Q1 2021 Earnings Results

Ligand Pharmaceuticals Beats on EPS — Stock Down 0.45%

Ligand Pharmaceuticals reported a strong earnings surprise on EPS, which was significantly above expectations. However, the stock reacted negatively, declining by 0.45%. This could indicate investor caution due to the lack of revenue data and future guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.41	N/A	+95.83%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on their operational performance. However, they did not provide specific guidance for future quarters.

Management highlighted strong performance in key areas despite the lack of revenue guidance.

They expressed confidence in the company's strategic direction moving forward.

Ligand Pharmaceuticals Beats on EPS — Stock Down 0.45%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS — Stock Down 0.45%

Key numbers

Management commentary